Context:

Amid ongoing tensions over FDA vaccine and biotech drug reviews, Dr. Vinay Prasad is leaving the agency for a second time, to return to UCSF at the end of April. His tenure has been marked by clashes over regulatory decisions, reversals, and calls for additional trials, framing a broader critique of FDA standards for rare-disease therapies and vaccines. The departure follows high-profile episodes, including a controversial stance on a Moderna mRNA flu vaccine and a public dispute over a Huntington’s disease gene therapy that prompted ethical questions and a press conference defense from the agency. The episode underscores enduring friction between industry, Congress, and critics of FDA processes, with more than a half-dozen therapies facing delays or new study requirements. Looking ahead, the FDA and its critics will likely continue negotiating speed, rigor, and patient safety in drug reviews and approvals.

Dive Deeper:

• FDA Commissioner Marty Makary announced that Prasad would depart at the end of April and return to his academic post at the University of California, San Francisco, marking a second exit within a year after controversial decisions affecting vaccines and rare-disease drugs.

• Prasad’s earlier tenure included a July ouster followed by a reinstatement less than two weeks later, backed by Health Secretary Robert F. Kennedy Jr. and Makary, illustrating the political resonance of his regulatory approach.

• One flashpoint was Prasad’s initial refusal to allow FDA review of a Moderna mRNA-based flu vaccine, a move Moderna publicly challenged before the agency reversed course and agreed to review pending an extra study.

• In another episode, UniQure’s Huntington’s disease gene therapy faced FDA pressure for a sham-surgery trial, a stance the company argued contradicted prior guidance and raised ethical concerns, prompting a highly unusual press conference by the FDA to defend the request.

• A senior FDA official characterized UniQure’s original study as 'stone cold negative' and declared, 'We have a failed product here,' highlighting internal frustrations with trials and outcomes that shape broader regulatory risk.

• The broader pattern cited notes that more than six drugmakers pursuing therapies for rare or hard-to-treat diseases received rejection letters or were asked to conduct additional studies, potentially delaying timelines and increasing costs.

• Prasad’s regulatory posture combined efforts to speed FDA drug reviews with new warnings and study requirements for certain biotech drugs and vaccines, aligning with Kennedy’s critique of vaccine regulation while provoking scrutiny of standard practices.